Rare Disease Report® Highlights Dr. Freyer on Hearing Loss Caused by Chemotherapy Agent During a Recent Interview

CRANBURY, N.J.--()--During the American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting, Rare Disease Report® the digital component of Rare Disease Communications®, conducted an interview featuring David Freyer, DO, MS, Children’s Hospital of Los Angeles and professor of pediatrics at Keck School of Medicine, University of Southern California, to better understand the effects of sodium thiosulfate in children and adults treated with cisplatin during chemotherapy.

Recent news identified cisplatin, a common chemotherapy agent, as a cause of hearing loss in children and adults undergoing chemotherapy. During the interview, Dr. Freyer stated, “In the United States alone, every year over 2,000 children and teenagers are treated with cisplatin. It’s been well known that it causes hearing loss in a proportion of patients, with younger patients more at risk, where incidents maybe 70 to 100 percent.”

While describing the significant impact of hearing loss in children, Dr. Freyer added, “In very young children, it’s not just the hearing loss, but it impacts learning, language acquisition, psycho-social development, school function, and a whole host of things that impair the quality of life both short- and long-term.”

Dr. Freyer said, “The damage is caused by chemotherapy itself and free radicals, or superoxide ions that damage the hearing apparatus in the cochlea.” He added, “Sodium thiosulfate is a scavenger that inactivates those damaging substances produced by the cisplatin.”

To view the interview featuring Dr. Freyer, please visit http://www.raredr.com/conferences/aspho2017/hearing-loss-in-cisplatin-treated-patients.

About Rare Disease Communications®

Rare Disease Communications® is a healthcare communications and media company focused on the rare disease community and dedicated to raising awareness of rare diseases and orphan drugs so that patients will be diagnosed and treated more efficiently. Rare Disease Communications® is part of the Michael J. Hennessy Associates, Inc. family of businesses, based in Cranbury, N.J. MJH Associates is dedicated to improving quality of life through healthcare education, research and communication. To learn more, visit http://www.mjhassoc.com.

Contacts

Rare Disease Report® Media:
Theresa Burek
tburek@mjhassoc.com
or
Surabhi Verma
sverma@mjhassoc.com

Release Summary

Rare Disease Report® interview with Dr. David Freyer

Contacts

Rare Disease Report® Media:
Theresa Burek
tburek@mjhassoc.com
or
Surabhi Verma
sverma@mjhassoc.com